Dr Lal Pathlabs Ltd
Dr Lal Pathlabs Ltd (LALPATHLAB)

Dr Lal Pathlabs Ltd (LALPATHLAB)

₹2514.92.83%

Key Stats

₹2423.85
Day's Price Range
₹2539
₹1805.55
52-Week Price Range
₹4059.7
1 Month Return-5.4 %
3 Month Return20.42 %
1 Year Return-39.47 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 4
76.12
EPS
Rank 1
₹32.79
BVPS
Rank 1
₹180.94
Dividend Yield
Rank 1
0.74%
ROE
Rank 1
25.55%
Price To Book Ratio
Rank 4
13.8
Debt To Asset
Rank 4
0.25

Company Information

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated nationwide network the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing patient diagnosis and the prevention monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national hub and spoke network that includes its National Reference Laboratory in New Delhi Regional Reference Lab in Kolkata and 214 other clinical laboratories 3095 patient service centers and 6995 pickup points as of 31 March 2020. Its customers include individual patients hospitals and other healthcare providers and corporate customers. The catalogue of services includes 455 test panels 2537 pathology tests and 1961 radiology and cardiology tests.Late Dr. Major S.K. Lal commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company Dr Lal Pathlabs Pvt LtdThe Company was incorporated as Dr. Lal PathLabs Private Limited a private limited company under the Companies Act 1956 with a certificate of incorporation granted by the RoC on February 14 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7 2015. Consequently the name of our Company was changed to Dr. Lal PathLabs Limited and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19 2015.The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10 stake each in Dr. Lal PathLabs subsidiaries M/s Paliwal Diagnostics Private Limited PDPL and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited a wholly owned subsidiary of the company with the company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Honble National Company Law Tribunal NCLT on October 23 2018 and December 11 2018 respectively. Pursuant thereto in accordance with the terms of the scheme Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1 2017 being the appointed date and consequently stands dissolved without winding up.The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70 stake in Dr. Lal Path Labs Bangladesh Pvt Limited DLPLB from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs DLPLB shall be acquiring the running diagnostic business of a soleproprietorship firm in Dhaka Bangladesh. On 12 December 2017 Dr. Lal PathLabs announced that the Board of Directors of the companys subsidiary Paliwal Diagnostics Private Limited at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre SPDC based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.Dr. Lal PathLabs Kolkata Reference Lab started testing of samples in early January 2018. The Worldclass Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena. During the FY2019 Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12 2018 respectively as wholly owned subsidiaries of the Company. As on 31 March 2019the company has 5 domestic and 3 overseas subsidiaries under its roof.The Board of Directors of your Company in their meeting held on February 3 2020 approved a Scheme of Amalgamation the Scheme between the Company and APL Institute of Clinical Laboratory Research Private Limited a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal New Delhi for approval of the Scheme of Amalgamation.During the FY2020 Companys Wholly Owned Subsidiary viz M/s PathLabs Unifiers Private Limited acquired 70 equity stake in M/s Centrapath Labs Private Limited and M/s APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6 2019 as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million Rs 7.10 million consisting of 9880 shares of KES 100.As on 31 March 2020the company has 7 domestic and 4 overseas subsidiaries under its roof.During the year 201920 the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares. During the quarter ended 30 June 2020the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltdthrough subscription of additional equity shares.Subsequent to the quarter ended 30 September 2020pursuant to approval of the Board of Directors of Pathlabs Unifiers Private LtdPUPLa whollyowned subsidiaryPUPL has signed binding term sheets on 06 November 2020for the acquisition of the business of Bindish Diagnostic Laboratory LLPGujaraton a going concern basisfor a purchase consideration not exceeding Rs 40 million and equity stake of 40 in ChanRe Diagnostic Services Private LtdBengalurufor a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services.During the quarter ended 31 December 2020the company has made a further investment of Rs 225 million in its whollyowned subsidiaryPathlabs Unifiers Private Ltdthrough subscription of additional equity shares. Also the company made a further investment of Rs 40 million in its whollyowned overseas subsidiaryDr.Lal Pathlabs Kenya Private Ltdthrough subscription of additional equity shares.
OrganisationDr Lal Pathlabs Ltd
HeadquartersNew Delhi
IndustryHealthcare